Baxter completes $3.9B acquisition of Gambro
THE ASSOCIATED PRESS September 6, 2013 8:18AM
DEERFIELD — Pharmaceutical company Baxter International Inc. has closed on its approximately $3.9 billion acquisition of Swiss dialysis products company Gambro AB.
Baxter, based in Deerfield, offered to buy Gambro in December 2012.
In July the European Union’s antitrust authority cleared Baxter’s bid for privately held Gambro. The European Commission said the buyout could go ahead on the condition that Baxter divest its renal replacement therapy, which serves patients suffering from acute kidney failure.
Gambro makes dialysis products for patients with acute or chronic kidney disease.
Baxter shares finished at $69.78 on Thursday. That is near the high end of their 52-week range of $58.76 to $74.60.